With respect to SGLT-2 inhibitors, studies demonstrated their beneficial effects on cardiac events, strokes and mortality outcomes in T2DM patients with CV comorbid conditions, along with a lower risk of hypoglycemia than other oral antidiabetics51–54. The gene discussed is SLC5A2; the disease is Hypoglycemia.